Background:
Migraine is typically divided into 2 headache frequency denominated categories, episodic migraine (EM) and chronic migraine (CM). Characterizing more narrow headache day frequency groups may be of value for better understanding the broad range of migraine experience and making treatment decisions.
Objective:
To characterize the impact and burden of migraine in 4 monthly headache day (MHD) categories.
Methods:
Respondents to the American Migraine Prevalence and Prevention Study 2005 survey who met criteria for migraine were categorized into low frequency episodic migraine (LFEM) 0-3, moderate frequency episodic migraine (MFEM) 4-7, high frequency episodic migraine (HFEM) 8-14, and CM with ≥15 headache days per month. Data including sociodemographics, headache features and symptomology, comorbidities, cutaneous allodynia, and severe migraine-related disability were compared among groups. We combined the low- and medium-frequency EM groups (L/MFEM) and compared them with the HFEM group in 1 set of models and compared the HFEM and CM groups in a second set of models. Binary logistic regression, linear regression, and ordered logistic regression were used depending upon the variable type and adjusted for sociodemographics.
Results:
Among 11,603 eligible respondents with migraine, 67.7% (7860/11,603) were categorized with LFEM, 17.7% (2051/11,603) with MFEM, 7.8% (898/11,603) with HFEM, and 6.8% (794/11,603) with CM. The mean age was 46 (SD 13.7), 80.2% (9301/11,603) were female, and 90.0% (10,187/11,323) were White, 6.9% were Black (784/11,323), and 3.1% (352/11,323) were identified as Other race(s). Individuals with HFEM differed from L/MFEM on a wide range of sociodemographic variables in the categories of headache features, disability, and comorbidities while few differences were found when modeling HFEM vs CM. In comparison with L/MFEM and HFEM, the HFEM group was more likely to have severe disability (P < .001 OR = 1.74 [1.42, 2.15]), chronic pain (P ≤ .007 OR = 1.35 [1.09, 1.69]), arthritis (P = .001 OR = 1.44 [1.15, 1.80]), high cholesterol (P = .005, OR = 1.37 [1.10, 1.70]), ulcers (P = .016, OR = 1.44 [1.07, 1.93]), and depression (Patient Health Questionnaire [PHQ-9]) (P < .001 OR = 1.50 [1.22, 1.84]).
Conclusion:
While rates of migraine symptoms, headache impact and disability, and comorbidities generally increased with increases in MHD frequency, respondents with HFEM and CM were remarkably similar on a broad range of variables including sociodemographics, disability/impact, and comorbidities. There were many more significant differences between the HFEM and L/MFEM groups on the same variables. Future work should use empirical strategies to identify naturally occurring groups and possibly reconsider the boundary between CM and HFEM.
Citing Articles
The unmet needs in management, the treatment gap and the burden of migraine in Greece: a Delphi consensus and focus group study from patients' perspective.
Vikelis M, Kourlaba G, Barba L, Bilias K, Barbalia E, Solakidi A
Front Neurol. 2025; 16:1558014.
PMID: 40066304
PMC: 11892325.
DOI: 10.3389/fneur.2025.1558014.
Unmet needs in the management of migraine in Greece from the perspective of medical experts: a Delphi consensus.
Kourlaba G, Vikelis M, Karapanayiotides T, Solakidi A, Trafalis D, Lioliou K
Front Neurol. 2025; 16:1556808.
PMID: 40040919
PMC: 11878100.
DOI: 10.3389/fneur.2025.1556808.
Anxiety Disorders, Anxious Symptomology and Related Behaviors Associated With Migraine: A Narrative Review of Prevalence and Impact.
Raudenska J, Macko T, Vodickova S, Buse D, Javurkova A
Curr Pain Headache Rep. 2025; 29(1):40.
PMID: 39878907
PMC: 11779792.
DOI: 10.1007/s11916-024-01312-9.
Role of Psychological Factors in Migraine.
Yu X, Tan G
Cureus. 2025; 16(12):e75858.
PMID: 39822418
PMC: 11736672.
DOI: 10.7759/cureus.75858.
Atogepant for migraine prevention: a meta-analysis of safety and efficacy in adults.
Raja A, Asim R, Shuja M, Raja S, Muhammad T, Bajaj S
Front Neurol. 2024; 15:1468961.
PMID: 39399876
PMC: 11466836.
DOI: 10.3389/fneur.2024.1468961.
Household income is associated with attack frequency, but not with the prevalence of headache: an analysis of self-reported headache in the general population in Germany.
Muller B, Gaul C, Reis O, Jurgens T, Kropp P, Ruscheweyh R
J Headache Pain. 2024; 25(1):164.
PMID: 39354353
PMC: 11443947.
DOI: 10.1186/s10194-024-01844-w.
Treatment patterns of patients with migraine eligible for anti-CGRP pathway monoclonal antibodies.
Khodavirdi A, Multani J, Oh S, Vuvu F, Bensink M, Stockl K
Front Neurol. 2024; 15:1433423.
PMID: 39165264
PMC: 11333223.
DOI: 10.3389/fneur.2024.1433423.
Quality of life and work productivity and activity impairment among online survey respondents with migraine across a range of headache frequency.
Ishii R, Sakai F, Sano H, Nakai M, Koga N, Matsukawa M
Front Neurol. 2024; 15:1440733.
PMID: 39045427
PMC: 11263292.
DOI: 10.3389/fneur.2024.1440733.
Headache/migraine-related stigma, quality of life, disability, and most bothersome symptom in adults with current versus previous high-frequency headache/migraine and medication overuse: results of the Migraine Report Card survey.
Buse D, Cady R, Starling A, Buzby M, Spinale C, Steinberg K
BMC Neurol. 2024; 24(1):232.
PMID: 38965567
PMC: 11223432.
DOI: 10.1186/s12883-024-03732-x.
Results of a Web-Based Survey on 2565 Greek Migraine Patients in 2023: Demographic Data, Imposed Burden and Satisfaction to Acute and Prophylactic Treatments in the Era of New Treatment Options.
Dermitzakis E, Argyriou A, Bilias K, Barmpa E, Liapi S, Rikos D
J Clin Med. 2024; 13(10).
PMID: 38792309
PMC: 11122074.
DOI: 10.3390/jcm13102768.
Real-world effectiveness and satisfaction with intravenous eptinezumab treatment in patients with chronic migraine: REVIEW, an observational, multi-site, US-based study.
Argoff C, Herzog S, Smith R, Kotak S, Sopina L, Saltarska Y
J Headache Pain. 2024; 25(1):65.
PMID: 38664605
PMC: 11044317.
DOI: 10.1186/s10194-024-01764-9.
An economic evaluation of eptinezumab for the preventive treatment of migraine in the UK, with consideration for natural history and work productivity.
Griffin E, Shirley G, Lee X, Awad S, Tyagi A, Goadsby P
J Headache Pain. 2024; 25(1):59.
PMID: 38637754
PMC: 11027549.
DOI: 10.1186/s10194-024-01749-8.
Reporting Quality and Risk of Bias Analysis of Published RCTs Assessing Anti-CGRP Monoclonal Antibodies in Migraine Prophylaxis: A Systematic Review.
Rikos D, Vikelis M, Dermitzakis E, Soldatos P, Rallis D, Rudolf J
J Clin Med. 2024; 13(7).
PMID: 38610729
PMC: 11012539.
DOI: 10.3390/jcm13071964.
Modeling the Effects of Formulary Exclusions: How Many Patients Could Be Affected by a Specific Exclusion?.
Sydor A, Bergin E, Kay J, Stone E, Popovian R
J Health Econ Outcomes Res. 2024; 11(1):86-93.
PMID: 38544720
PMC: 10970716.
DOI: 10.36469/001c.94544.
Societal and economic burden of migraine in Spain: results from the 2020 National Health and Wellness Survey.
Garcia-Azorin D, Moya-Alarcon C, Armada B, Sanchez Del Rio M
J Headache Pain. 2024; 25(1):38.
PMID: 38486155
PMC: 10941425.
DOI: 10.1186/s10194-024-01740-3.
Harris Poll Migraine Report Card: population-based examination of high-frequency headache/migraine and acute medication overuse.
Starling A, Cady R, Buse D, Buzby M, Spinale C, Steinberg K
J Headache Pain. 2024; 25(1):26.
PMID: 38408888
PMC: 10895775.
DOI: 10.1186/s10194-024-01725-2.
Effects of OnabotulinumtoxinA on Allodynia and Interictal Burden of Patients with Chronic Migraine.
Argyriou A, Dermitzakis E, Rikos D, Xiromerisiou G, Soldatos P, Litsardopoulos P
Toxins (Basel). 2024; 16(2).
PMID: 38393184
PMC: 10891839.
DOI: 10.3390/toxins16020106.
The impacts of migraine on functioning: Results from two qualitative studies of people living with migraine.
Mangrum R, Bryant A, Gerstein M, McCarrier K, Houts C, McGinley J
Headache. 2024; 64(2):156-171.
PMID: 38235605
PMC: 10922598.
DOI: 10.1111/head.14664.
Role of Yoga as Adjunctive Therapy for Migraines: A Narrative Review of the Literature.
Kachhadia M, Khalil Z, Shah S, Fawad M, Sajjad H, Yadav K
Cureus. 2023; 15(11):e48434.
PMID: 38073999
PMC: 10701189.
DOI: 10.7759/cureus.48434.
Rethinking headache as a global public health case model for reaching the SDG 3 HEALTH by 2030.
Martelletti P, Leonardi M, Ashina M, Burstein R, Cho S, Charway-Felli A
J Headache Pain. 2023; 24(1):140.
PMID: 37884869
PMC: 10604921.
DOI: 10.1186/s10194-023-01666-2.